Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials
- 6 July 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 19 (12) , 1273-1281
Abstract
To evaluate the efficacy and safety of sotatercept, an activin signaling inhibitor, in pulmonary arterial hypertension (PAH). We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing sotatercept versus placebo in PAH. We calculated pooled risk ratios (RR) and mean differences (MD) with their 95% confidence intervals (CI) using a random-effects model. Heterogeneity was assessed with I2 statistics. The GRADE approach was used to assess the certainty of evidence. Three RCTs comprising 601 patients were included. Compared to placebo, sotatercept significantly improved 6-minute walk distance (MD 40.57 m; 95% CI 26.64 to 54.5; p < 0.01), and WHO functional class (RR 2.04; 95% CI 1.53 to 2.7; p < 0.01). Sotatercept reduced pulmonary vascular resistance (MD -233.18 dyn·sec·cm-5; 95% CI -295.84 to -170.52; p < 0.01) and pulmonary artery pressure (MD -14.94 mmHg; 95% CI -19.62 to -10.27; p < 0.01) at study end. No significant differences were observed in all-cause mortality or NT-proBNP levels. Sotatercept was associated with epistaxis, increased hemoglobin, and telangiectasia adverse events. Sotatercept improves exercise capacity, WHO functional class and pulmonary hemodynamics in PAH, with an acceptable safety profile. Long-term studies are needed to confirm sustained benefits. www.crd.york.ac.uk/prospero identifier is CRD420251032174.Keywords
This publication has 29 references indexed in Scilit:
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathNew England Journal of Medicine, 2025
- Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial HypertensionAmerican Journal of Cardiovascular Drugs, 2024
- A new day has come: Sotatercept for the treatment of pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2024
- Mechanisms and treatment of pulmonary arterial hypertensionNature Reviews Cardiology, 2024
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2023
- Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial HypertensionChest, 2022
- Sotatercept for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertensionScience Translational Medicine, 2020
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011